Myeloma cells are highly sensitive to the granule exocytosis pathway mediated by WT1-specific cytotoxic T lymphocytes

Clinical Cancer Research

Volumn 10, Issue 21, 2004, Pages 7402-7412

  Azuma, Taichi ^a   Otsuki, Takemi ^b   Kuzushima, Kiyotaka ^c   Froelich, Christopher J ^d   Fujita, Shigeru ^a   Yasukawa, Masaki ^a  

^a EHIME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KAWASAKI MEDICAL SCHOOL   (Japan)

^c AICHI CANCER CENTER HOSPITAL   (Japan)

^d Evanston NW Hlthcare Res Institute ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHROMIUM 51; GAMMA INTERFERON; MESSENGER RNA; PERFORIN; TUMOR ANTIGEN; WT1 PROTEIN;

ARTICLE; CANCER IMMUNOTHERAPY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; CYTOTOXICITY; EXOCYTOSIS; FLOW CYTOMETRY; GENE EXPRESSION; HLA SYSTEM; HUMAN; HUMAN CELL; LYMPHOMA CELL; MONONUCLEAR CELL; MULTIPLE MYELOMA; MYELOMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANTIGENS, NEOPLASM; BONE MARROW CELLS; CALCIUM; CELL LINE; CELL LINE, TUMOR; CHROMIUM; CYTOPLASMIC GRANULES; DOSE-RESPONSE RELATIONSHIP, DRUG; EGTAZIC ACID; ENZYME-LINKED IMMUNOSORBENT ASSAY; EXOCYTOSIS; FLOW CYTOMETRY; GENES, MHC CLASS I; HUMANS; IMMUNOTHERAPY; INTERFERON TYPE II; LYMPHOMA; MACROLIDES; MEMBRANE GLYCOPROTEINS; MULTIPLE MYELOMA; PEPTIDES; PORE FORMING CYTOTOXIC PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; T-LYMPHOCYTES, CYTOTOXIC; TREATMENT OUTCOME; WT1 PROTEINS;

EID: 8444224189     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-04-0825     Document Type: Article

References (53)

1. Anderson KC, Shaughnessy JD Jr, Barlogie B, Harousseau JL, Roodman GD. Multiple myeloma. Hematology 2002;214-40.
2. Kuehl WM, Bergsagel PL. Multiple myeloma: evolving genetic events and host interactions. Nat Rev Cancer 2002;2:175-87.
3. Kumar A, Loughran T, Alsina M, Durie BG, Djulbegovic B. Management of multiple myeloma: a systematic review and critical appraisal of published studies. Lancet Oncol 2003;4:293-304.
4. Hayashi T, Hideshima T, Anderson KC. Novel therapies for multiple myeloma. Br J Haematol 2003;120:10-7.
5. Call KM, Glaser T, Ito CY, et al. Isolation and characterization of a zinc finger polypeptide gene at the human chromosome 11 Wilms' tumor locus. Cell 1990;60:509-20.
6. Rauscher FJ III. The WT1 Wilms tumor gene product: a developmentally regulated transcription factor in the kidney that functions as a tumor suppressor. FASEB J 1993;7:896-903.
7. Park S, Schalling M, Bernard A, et al. The Wilms tumor gene WT1 is expressed in murine mesoderm-derived tissues and mutated in a human mesothelioma. Nat Genet. 1993;4:415-20.
8. Pritchard-Jones K, Fleming S, Davidson D, et al. The candidate Wilms' tumor gene is involved in genitourinary development. Nature (Lond) 1990;346:194-7.
9. Lee SB, Haber DA. Wilms tumor and the WT1 gene. Exp Cell Res 2001;264:74-99.
10. Baird PN, Simmons PJ. Expression of the Wilms' tumor gene (WT1) in normal hemopoiesis. Exp Hematol 1997;25:312-20.
11. Miwa H, Beran M, Saunders GF. Expression of the Wilms' tumor gene (WT1) in human leukemias. Leukemia (Baltimore) 1992;6:405-9.
12. Inoue K, Sugiyama H, Ogawa H, et al. WT1 as a new prognostic factor and a new marker for the detection of minimal residual disease in acute leukemia. Blood 1994;84:3071-9.
13. Brieger J, Weidmann E, Fenchel K, et al. The expression of the Wilms' tumor gene in acute myelocytic leukemias as a possible marker for leukemic blast cells. Leukemia (Baltimore) 1994;8:2138-43.
14. Menssen HD, Renkl H, Rodeck U, et al. Presence of Wilms' tumor gene (wt1) transcripts and the WT1 nuclear protein in the majority of human acute leukemias. Leukemia (Baltimore) 1995;9:1060-7.
15. Ogawa H, Tamaki H, Ikegame K, et al. The usefulness of monitoring WT1 gene transcripts for the prediction and management of relapse following allogeneic stem cell transplantation in acute type leukemia. Blood 2003;101:1698-704.
16. + cytotoxic T-lymphocyte clone specific for WT1 peptide. Blood 2000;95:286-93.
17. Russell JH, Ley TJ. Lymphocyte-mediated cytotoxicity. Annu Rev Immunol 2002;20:323-70.
18. + CTL directed against herpes simplex virus-infected cells. J Immunol 1999;162:6100-6.
19. + cytotoxic T lymphocytes in humans. Blood 2000;95:2352-5.
20. + T lymphocytes: analysis using the combination of hereditary perforin-deficient effector cells and Fas-deficient target cells. J Immunol 2003;170:2205-13.
21. Azuma T, Makita M, Ninomiya K, et al. Identification of a novel WT1-derived peptide which induces human leucocyte antigen-A24-restricted anti-leukaemia cytotoxic T lymphocytes. Br J Haematol 2002;116:601-3.
22. + T cells. J Immunol 1991;146:1341-7.
23. Makita M, Hiraki A, Azuma T, et al. Antilung cancer effect of WT1-specific cytotoxic T lymphocytes. Clin Cancer Res 2002;8:2626-31.
24. Froelich CJ, Turbov J, Hanna W. Human perform: rapid enrichment by immobilized metal affinity chromatography (IMAC) for whole cell cytotoxicity assays. Biochem Biophys Res Commun 1996;229:44-9.
25. Froelich CJ, Orth K, Turbov J, et al. New paradigm for lymphocyte granule-mediated cytotoxicity. Target cells bind and internalize granzyme B, but an endosomolytic agent is necessary for cytosolic delivery and subsequent apoptosis. J Biol Chem 1996;271:29073-9.
26. + human cytotoxic T cell clones directed against herpes simplex virus. J Immunol 1988;140:3419-25.
27. Kataoka T, Shinohara N, Takamiya H, et al. Concanamycin A, a powerful tool for characterization and estimation of contribution of perform- and Fas-based lytic pathways in cell-mediated cytotoxicity. J Immunol 1996;156:3678-86.
28. + T-cell epitopes by a computer algorithm and an enzyme-linked immunospot assay. Blood 2001;98:1872-81.
29. Lowin B, Mattman C, Hahne M, Tschopp J. Comparison of Fas(Apo-1/CD95)- and perforin-mediated cytotoxicity in primary T lymphocytes. Int Immunol 1996;8:57-63.
30. Yotnda P, Firat H, Garcia-Pons F, et al. Cytotoxic T cell response against the chimeric p210 BCR-ABL protein in patients with chronic myelogenous leukemia. J Clin Investig 1998;101:2290-6.
31. + T cells with cytotoxic activity against leukemic cells from patients with chronic myeloid leukemia. Blood 1998;91:977-83.
32. Clark RE, Dodi A, Hill SC, et al. Direct evidence that leukemic cells present HLA-associated immunogenic peptides derived from the BCR-ABL b3a2 fusion protein. Blood 2001;98:2887-93.
33. + cytotoxic T-cell clones specific for bcr-abl b3a2 fusion peptide augment colony formation by chronic myelogenous leukemia cells in a b3a2-specific and HLA-DR-restricted manner. Blood 1998;92:3355-61.
34. + T lymphocytes. Leukemia (Baltimore) 2002;16:2400-7.
35. + T lymphocytes. Blood 2001;98:1498-505.
36. Yotnda P, Garcia F, Peuchmaur M, et al. Cytotoxic T cell response against the chimeric ETV6-AML1 protein in childhood acute lymphoblastic leukemia. J Clin Investig 1998;102:455-62.
37. Sykulev Y, Joo M, Vturina I, Tsomides TJ, Eisen HN. Evidence that a single peptide-MHC complex on a target cell can elicit a cytolytic T cell response. Immunity 1996;4:565-71.
38. Jiang SB, Ojcius DM, Persechini PM, Young JD. Resistance of cytolytic lymphocytes to perforin-mediated killing. Inhibition of perform binding activity by surface membrane proteins. J Immunol 1990;144:998-1003.
39. Muller C, Tschopp J. Resistance of CTL to perforin-mediated lysis. Evidence for a lymphocyte membrane protein interacting with perform. J Immunol 1994;153:2470-8.
40. Balaji KN, Schaschke N, Machleidt W, Catalfamo M, Henkart PA. Surface cathepsin B protects cytotoxic lymphocytes from self-destruction after degranulation. J Exp Med 2002;196:493-503.
41. Bird CH, Sutton VR, Sun J, et al. Selective regulation of apoptosis: the cytotoxic lymphocyte serpin proteinase inhibitor 9 protects against granzyme B-mediated apoptosis without perturbing the Fas cell death pathway. Mol Cell Biol 1998;18:6387-98.
42. Odeberg J, Browne H, Metkar S, et al. The human cytomegalovirus protein UL16 mediates increased resistance to natural killer cell cytotoxicity through resistance to cytolytic proteins. J Virol 2003;77:4539-45.
43. Lehmann C, Zeis M, Schmitz N, Uharek L. Impaired binding of perform on the surface of tumor cells is a cause of target cell resistance against cytotoxic effector cells. Blood 2000;96:594-600.
44. Metkar SS, Aguilar-Santelises M, Wang B, Froelich CJ. Flow cytometry cannot assess surface binding of perform to target cells. Blood 2001;97:2181-3.
45. + T cells. Blood 2000;96:2828-33.
46. Titzer S, Christensen O, Manzke O, et al. Vaccination of multiple myeloma patients with idiotype-pulsed dendritic cells: immunological and clinical aspects. Br J Haematol 2000;108:805-16.
47. Rasmussen T, Hansson L, Osterborg A, Johnsen HE, Mellstedt H. Idiotype vaccination in multiple myeloma induced a reduction of circulating clonal tumor B cells. Blood 2003;101:4607-10.
48. Noto H, Takahashi T, Makiguchi Y, et al. Cytotoxic T lymphocytes derived from bone marrow mononuclear cells of multiple myeloma patients recognize an underglycosylated form of MUC1 mucin. Int Immunol 1997;9:791-8.
49. Chiriva-Internati M, Wang Z, Salati E, et al. Sperm protein 17 (Sp17) is a suitable target for immunotherapy of multiple myeloma. Blood 2002;100:961-5.
50. Lim SH, Wang Z, Chiriva-Intemati M, Xue Y. Sperm protein 17 is a novel cancer-testis antigen in multiple myeloma. Blood 2001;97:1508-10.
51. Wang Z, Zhang Y, Liu H, et al. Gene expression and immunologic consequence of SPAN-Xb in myeloma and other hematologic malignancies. Blood 2003;101:955-60.
52. van Baren N, Brasseur F, Godelaine D, et al. Genes encoding tumor-specific antigens are expressed in human myeloma cells. Blood 1999;94:1156-64.
53. Pellat-Deceunynck C. Tumour-associated antigens in multiple myeloma. Br J Haematol 2003;120:3-9.